Navigation Links
Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory
Date:7/15/2008

SAN DIEGO, July 15 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that E.J. Brandreth has joined the company as Vice President of Quality and Regulatory. In this role, Mr. Brandreth will be responsible for leading Althea's quality and compliance programs, while overseeing the regulatory support activities, which are required to facilitate the launch of commercial manufacturing services.

(Photo: http://www.newscom.com/cgi-bin/prnh/20020925/LAW010LOGO)

"We are very excited to welcome E.J. Brandreth to Althea. The diverse experience he brings to the company is particularly valuable, as it spans everything from clinical development of innovative products, to the preparation and validation required for commercial launch of successful biopharmaceuticals. His background in clinical and commercial biological products is a perfect fit for the expanding scope of projects at Althea," stated Dr. Magda Marquet, President and Co-CEO of Althea Technologies.

Mr. Brandreth brings over fifteen years of experience in the regulatory and quality assurance fields for the biotechnology and pharmaceutical industries. Prior to joining Althea Technologies, he was Vice President of Quality at Favrille, Inc., where he had oversight of Quality Control, Quality Assurance, Validation and Metrology. In the course of his career he has managed the validation of 11 different biotechnology facilities, and led the Process Validation Programs for five CBER/EMEA product launches. Previous to Favrille, Mr. Brandreth was Senior Director of QA at BioMarin Pharmaceuticals, Inc. where he supported a variety of clinical products and launched two commercial products. Prior to that, he held management positions in QA, Validation and Regulatory Affairs at IDEC Pharmaceuticals, where he assisted in the development and launch of Zevalin(R) and Rituxan(R), CBER's first approved monoclonal antibody for cancer. Additionally, Mr. Brandreth has helped to develop two Parenteral Drug Association (PDA) technical reports.

E.J. Brandreth added, "I am very pleased to join the outstanding team of professionals here at Althea Technologies. I've watched the company's growth and I am really happy that I can call upon my experience to help assure the quality, compliance and facility validation efforts underway, which will best serve Althea's clients. I'm joining Althea as the activities focused upon the release of the newly constructed state-of-the-art commercial-scale facility head into high gear, so I will be able to jump right in as we write this exciting new chapter in the company's history."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling. For more information, visit http://www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: